Comments: Growth in the quarter was driven by Mounjaro, with sales up 60% to $3.5 billion, and Zepbound, with sales of $1.9 billion. New Products revenue, which consists of Ebglyss, Jaypirca, Kisunla, ...

EXTON, PA, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The FDA's approval of Eli Lilly’s Omvoh for Crohn’s disease marks a significant milestone as the therapy becomes the second IL-23 inhibitor ...

FRANKFURT (Reuters) - The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization and related programmes risks harming millions of ...

The Food and Drug Administration (FDA) has approved Omvoh ® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults. Mirikizumab is a humanized immunoglobulin G4 ...

Omvoh (mirikizumab-mrkz) has potential interactions with certain vaccines and health conditions. These interactions could cause harmful effects in some people. Omvoh is used in adults to treat ...

You may not see anything wrong with flying when you're feeling a bit run down, but a pilot explained why it's a bad idea. Captain Jaimes García, who has more than 156,000 followers on TikTok, shared a ...

The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults. Wearable devices can identify ...

The senior vice president at Lilly Immunology Development discusses recent developments with Omvoh. The European Medicines Agency’s Committee for Medicinal Products for Human Use recently issued a ...

The treatment was approved in 2024 for chronic graft-vs-host disease after failure of at least 2 prior lines of systemic therapy in patients weighing at least 40kg. The Food and Drug Administration ...

The recent approval of Omvoh for Crohn's disease, following its success in ulcerative colitis, demonstrates Eli Lilly's commitment to broadening its therapeutic reach. One of the key challenges ...